-
UPDATE: Somaxon Pharma Trading Over 15% Pre-Market On Collaboration With Paladin
Wednesday, June 8, 2011 - 9:26am | 89Somaxon Pharmaceuticals (NASDAQ: SOMX) and Paladin Labstoday announced that they have entered into an exclusive collaboration under which Paladin will commercialize Silenor (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South America and Africa...
-
Bank Of America Reports On Botox Headache Treatment From AGN
Wednesday, June 8, 2011 - 8:21am | 174Bank of America is reiterating its Buy rating and its $90 price target on Allergan (NYSE: AGN) following a survey conducted for the market analyst. In the report, Bank of America writes, “Early read supports Botox potential for migraine We commissioned a survey of 75 neurologists that treat...
-
Somaxon Announce Milestone Payments of Up to $129M
Wednesday, June 8, 2011 - 8:08am | 269Somaxon Pharmaceuticals (NASDAQ: SOMX) and Paladin Labstoday announced that they have entered into an exclusive collaboration under which Paladin will commercialize Silenor (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South America and...
-
Somaxon-Paladin Report Silenor® Ex-US Pact
Wednesday, June 8, 2011 - 8:01am | 182Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) and Paladin Labs Inc. today announced that they have entered into an exclusive collaboration underwhich Paladin will commercialize Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South...
-
FDA Approves Updates to Lilly's HumalogLabel
Wednesday, June 8, 2011 - 8:01am | 92Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration approved the company's supplemental new drug application with the following updates to the Humalog label: continuous insulin infusion pump therapy in children 4 years of age and over with type 1 diabetes...
-
UPDATE: Merck and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
Wednesday, June 8, 2011 - 7:26am | 241Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Intercell AG today announced that following a detailed analysis of the data from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection,...
-
Pfizer Conducts First "Virtual" Clinical Trial Allowing Patients to Participate Regardless Of Geography
Tuesday, June 7, 2011 - 3:01pm | 84Pfizer Inc. (NYSE: PFE) announced today that it is conducting the first-ever randomized clinical trial under an investigational new drug application that manages study participation entirely using electronic tools and allows patients to participate in the clinical trial regardless of their...
-
Mylan Receives Approval for Generic Version of Aricept® Tablets
Tuesday, June 7, 2011 - 1:14pm | 132Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5 mg and 10 mg, the generic version of...
-
Calls Purchased on Elan Corporation
Tuesday, June 7, 2011 - 11:56am | 129Shares of Elan Corporation (NYSE: ELN) are higher on the session by 5.44%, currently trading at $9.88. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name today. A...
-
Amarin Falling Again
Tuesday, June 7, 2011 - 10:49am | 129Shares of biotech Amarin Corp. (NASDAQ: AMRN) fell more than 7% on Monday, and at one point were trading more than 12% lower. The stock is getting hit again on Tuesday, falling nearly 3% to $16.69 in early trade. The sell-off yesterday was likely attributable to some comments from the CEO at an...
-
Court Certifies Overtime Class Action Against Forest Labs, According to The Ottinger Firm
Tuesday, June 7, 2011 - 8:40am | 107A class action alleging Forest Labs (NYSE: FRX) pharmaceutical sales representatives were unlawfully denied overtime pay has been certified by a New York federal court, The Ottinger Firm, P.C., announced today. U.S. District Judge William H. Pauley, of the Southern District of New York, granted...
-
Citi's Thoughts on Pfizer's ASCO Investor Meeting
Tuesday, June 7, 2011 - 8:39am | 190Pfizer Inc. (NYSE: PFE) summarized its oncology pipeline at an investor meeting at the American Society of Clinical Oncology (ASCO) meeting in Chicago last evening, Citi reports. “PFE reviewed data presented on late-stage products including crizotinib, axitinib & bosutinib,” Citi writes. “PFE...
-
Bank of America Merrill Lynch Maintains Buy on Merck & Co.
Tuesday, June 7, 2011 - 8:07am | 109Bank of America Merrill Lynch is out with its report today on Merck & Co. (NYSE: MRK), maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "Merck offers a good mix of low valuation, track record of returning cash to shareholders, and pipeline optionality, in our view....
-
Cadence Pharmaceuticals Announces Addition of OFIRMEV Injection to U.S. Military's Joint Deployment Formulary
Tuesday, June 7, 2011 - 8:04am | 129Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that OFIRMEV® (acetaminophen) injection has been added to the U.S. Department of Defense's Joint Deployment Formulary, the core list of pharmaceutical products required for theater-level care of deployed forces. The U.S. Food and Drug...
-
CoreSite, Interxion Announce Transatlantic Cloud Computing Data Center Alliance
Tuesday, June 7, 2011 - 8:03am | 199CoreSite (NYSE: COR) today announced a transatlantic, cloud computing-focused data center alliance with INTERXION HOLDING NV (NYSE: INXN). The alliance addresses dual-continent demand from cloud companies looking for data center space in the U.S. and Europe as well as cloud customers of both...